Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review Authors: Adèle Meola, Romain Appay, Benoit Testud, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Alexandre Bertucci, Didier Autran, Thomas Graillon, Kaissar Farah, Laetitia Padovani, Isabelle Pougnet, Isabelle Nanni, Olivier Chinot, Emeline Tabouret, Vincent Harlay Published: 2026 ABSTRACT ObjectivesWe report the case of an adult-type diffuse glioma with spinal leptomeningeal dissemination, corresponding to a new molecularly methylation class, identified as "Adult-type diffuse high-grade glioma, IDH-wildtype, subtype E," using the Heidelberg Epignostix CNS Tumor Classifier v12.8.MethodsClinical, histo-molecular, cerebrospinal fluid analyses and neuro-radiological data were recorded.ResultsA 43-year-old man was diagnosed 5 years ago with a diffuse glioma and subsequent spinal leptomeningeal dissemination. He received radiochemotherapy based on temozolomide followed by monthly temozolomide (6 months) but relapsed 15 months later. After three additional therapeutic lines, bevacizumab was introduced, achieving a clinical and imaging response with subtotal regression of lesions. To date, glioblastoma remains under control, 5 years after diagnosis and 3 years after bevacizumab introduction.DiscussionWe describe an unusual prolonged response to bevacizumab in a new subtype of adult-type diffuse high-grade glioma, with spinal leptomeningeal dissemination. Despite frequent dreadful prognosis in patients treated for high-grade gliomas, there are rare long-term responder patients. This situation remains unclear, particularly in the context of spinal leptomeningeal dissemination. The identification of new subtypes could help differentiate between miscellaneous prognostic group. It would be relevant to consider these subgroups in future clinical trials. Diffuse gliomas are a heterogenous group of central nervous system (CNS) tumors with distinct genetic features [1]. Genome-wide DNA methylation profiling has become a powerful tool for classifying CNS tumors and discovering new subtypes [2]. The 2021 WHO CNS tumor classification offers a standardized framework for naming these newly identified tumor types based on molecular characteristics. Spinal leptomeningeal dissemination (SLD) of high-grade gliomas (HGG) is a rare condition (2–20% in post-mortem studies) with terrible prognosis [3]. Treatments like Temozolomide (TMZ) and Bevacizumab (BEV), an anti-vascular endothelial growth factor monoclonal antibody, offer limited efficacy for HGG with SLD [4, 5]. We report a rare case of secondary SLD of an intracranial glioma with an extended response to bevacizumab. Case description We report the case of a 43-year-old man, without past medical history or family history of oncological or neurological conditions. He presented with nausea and ataxia in July 2019. Brain MRI showed a heterogeneous left cerebellar mass with contrast enhancement (Fig. 1). Complete surgical resection was performed. Histopathological analysis revealed a diffusely infiltrating, highly cellular tumor composed of poorly differentiated glial cells exhibiting nuclear atypia and marked cellular and nuclear polymorphism, including numerous multinucleated giant cells. Mitotic activity was significantly elevated. Abnormal vascularization was observed, characterized by microvascular proliferation and necrosis with perinecrotic palisading. Immunohistochemical techniques demonstrated that the tumor cells expressed the OLIG2 protein but not GFAP. Loss of nuclear expression of ATRX and overexpression of p53 were observed, while no staining was detected with the antibody directed against the IDH1 R132H mutation. Evaluation of mismatch repair (MMR) proteins revealed a loss of nuclear expression of MLH1 and PMS2, whereas MSH2 and MSH6 were retained. Complementary molecular biology techniques were performed. Next-generation sequencing (NGS) of a targeted gene panel confirmed mutations in ATRX, TP53, MLH1, and PMS2, as identified by immunohistochemistry. Additionally, POLE p.P436S mutation as well as RB1, and LZTR1 mutations were detected. No mutations were identified in IDH1/2, BRAF, H3.3, H3.1, or the TERT promoter. Tumor mutational burden (TMB) was unavailable. Finally, methylation profiling revealed that this tumor corresponded to the methylation class "MC Adult-type diffuse HGG, IDH-wildtype, subtype E," with a classification score of 0.99 using version 12.8 of the Heidelberg classifier (Fig. 2). MGMT promotor was unmethylated. Initial Karnofsky performance status (KPS) was 90%. Standard treatment for patients with glioblastoma was performed, including a first concomitant radiotherapy-chemotherapy (60 Gy in 30 fractions and TMZ), followed by 6 cycles of TMZ. Fifteen months later, in July 2021, the patient presented with ataxia. Brain MRI showed right acoustic-facial bundle and paraventricular lesions. Spinal cord MRI showed a T5-T6 and a L2 lesions (Fig. 1). Second-line chemotherapy was started with BCNU 110 mg/m2 D1 and TMZ 110 mg/m2 D1-D5 with progressive disease after one cycle, 6 weeks later. Then, the patient was treated with stereotactic radiotherapy on intracranial (30 Gy in 6 fractions) and spinal cord T5-T6 (1 single fraction of 10 Gy) lesions. Due to headaches and nausea, corticosteroid therapy was initiated at a dose of 1 mg/kg/day. Because of potential tumoral hypermutated profile, immunotherapy was proposed (anti-programmed death-1 (PD1); pembrolizumab, (2 mg/kg D1;D21), with decreased dose of corticosteroid (10 mg/day). After 3 cycles, a clinical deterioration was observed. MRI showed new nodular intraventricular lesions and diffuse leptomeningeal dissemination (Fig. 3) corresponding to radiological disease progression according to i-RANO criteria. A few days after increasing the corticosteroid dose (2 mg/kg/day), a fourth line of treatment was initiated by BEV (10 mg/kg D1;D15). After 2 months of treatment, the patient’s ataxia improved significantly, which allowed us to discontinue corticosteroid therapy. As expected with BEV, MRI showed regression of the brain lesions and subtotal reduction of spinal leptomeningeal contrast enhancements. Currently, 6 years from the diagnosis, 4 years from BEV initiation and 18 months after BEV discontinuation, the patient continues to show controlled disease. KPS is 90%, with slight residual ataxia.Fig. 1Preoperative and relapse imaging. A The preoperative brain MRI shows a heterogeneous solid enhanced left cerebellar mass (arrow) on axial T1-weighted image post contrast (A). B The follow-up T1-WI post-contrast brain image (top) reveals a leptomeningeal lesion (arrowhead) of the right internal auditory canal (top). The left cerebellar operative cavity is normal (arrow). Spinal cord MRI (bottom left) shows a thoracic meningeal lesion (arrowhead) with no cauda equina root lesion (bottom right). C The follow-up imaging shows progression of the right internal auditory canal lesion (arrowhead) and the thoracic intradural lesion (arrowhead), as well as a new lesion (arrowhead) of the cauda equina roots. D Further progression of intracranial and spinal lesions (arrowheads) after one cycle of Temozolomide-BCNUFig. 2Histomolecular characteristics of the case. Histopathological analysis revealed a high-grade glioma with marked nuclear pleomorphism, including the presence of giant cells (A). Immunohistochemical analysis demonstrated expression of the glial protein OLIG2 (B) but an absence of GFAP expression (C). Overexpression of p53 (D) was observed in association with loss of nuclear expression of ATRX (E), while no mutation in IDH1 R132H was detected (F). Loss of nuclear expression of MLH1 and PMS2 was also noted (G, H). The proliferation index, as assessed by Ki67, was significantly elevated (I). The copy number variation (CNV) profile derived from methylation analysis revealed no notable chromosomal abnormalities except for gains on chromosomes 20 and 21 (J)Fig. 3Leptomeningeal dissemination and complete response. (A)The follow-up T1-WI post-contrast brain image (top) reveals new nodular intraventricular lesions (arrowheads) and T1-WI post-contrast spinal cord images (bottom left and right) show diffuse leptomeningeal dissemination (arrowheads) (B) Regression of brain (top) lesions (arrowheads) and partial regression of spinal leptomeningeal dissemination (bottom left and right) after introduction of BEV treatment (C) The latest available follow-up imaging shows a complete response with regression of all intracranial (top) and spinal (bottom left and right) lesions (arrowheads) Preoperative and relapse imaging. A The preoperative brain MRI shows a heterogeneous solid enhanced left cerebellar mass (arrow) on axial T1-weighted image post contrast (A). B The follow-up T1-WI post-contrast brain image (top) reveals a leptomeningeal lesion (arrowhead) of the right internal auditory canal (top). The left cerebellar operative cavity is normal (arrow). Spinal cord MRI (bottom left) shows a thoracic meningeal lesion (arrowhead) with no cauda equina root lesion (bottom right). C The follow-up imaging shows progression of the right internal auditory canal lesion (arrowhead) and the thoracic intradural lesion (arrowhead), as well as a new lesion (arrowhead) of the cauda equina roots. D Further progression of intracranial and spinal lesions (arrowheads) after one cycle of Temozolomide-BCNU Histomolecular characteristics of the case. Histopathological analysis revealed a high-grade glioma with marked nuclear pleomorphism, including the presence of giant cells (A). Immunohistochemical analysis demonstrated expression of the glial protein OLIG2 (B) but an absence of GFAP expression (C). Overexpression of p53 (D) was observed in association with loss of nuclear expression of ATRX (E), while no mutation in IDH1 R132H was detected (F). Loss of nuclear expression of MLH1 and PMS2 was also noted (G, H). The proliferation index, as assessed by Ki67, was significantly elevated (I). The copy number variation (CNV) profile derived from methylation analysis revealed no notable chromosomal abnormalities except for gains on chromosomes 20 and 21 (J) Leptomeningeal dissemination and complete response. (A)The follow-up T1-WI post-contrast brain image (top) reveals new nodular intraventricular lesions (arrowheads) and T1-WI post-contrast spinal cord images (bottom left and right) show diffuse leptomeningeal dissemination (arrowheads) (B) Regression of brain (top) lesions (arrowheads) and partial regression of spinal leptomeningeal dissemination (bottom left and right) after introduction of BEV treatment (C) The latest available follow-up imaging shows a complete response with regression of all intracranial (top) and spinal (bottom left and right) lesions (arrowheads) Results and discussion The case report was conducted after obtaining the patient’s written consent and collecting relevant information from the medical records of the neuro-oncology department, at “La Timone” university hospital in Marseille. Our case corresponds to a HGG with SLD and unusual histopathological findings, characterized by marked nuclear pleomorphism, including giant cells, along with an immunophenotype indicative of alterations in p53, ATRX, MLH1 and PMS2. These alterations, as well as an associated POLE p.P436S mutation, located in the exonuclease domain and described as a driver mutation, were confirmed through molecular biology analyses [6]. The methylation profile corresponded to a newly identified tumor class, designated as "MC Adult-type diffuse high-grade glioma, IDH-wildtype, subtype E" (Fig. 2), using the Heidelberg Epignostix CNS Tumor Classifier v12.8. In Singh’s study, over 40 cases of MC Adult-type diffuse high-grade glioma, IDH-wildtype, subtype E were identified, with a male predominance (58%) and a median age at diagnosis of 11 years, suggesting a predominantly pediatric population—younger than our patient. Survival data revealed a median overall survival exceeding 5 years, which aligns with the favorable outcome observed in our patient. While MGMT promoter methylation is classically known as a favorable molecular prognostic factor, it is found in only 12% of patients with MC Adult-type diffuse high-grade glioma, IDH-wildtype, subtype E, as seen in our patient, who did not exhibit MGMT promoter methylation. Genomic analyses highlighted a high frequency of POLE gene mutations, as seen in our patient, along with an elevated tumor mutational burden [7]. Subgroups of HGG, currently being identified with the contribution of methylation profiling, could have a meningeal tropism and, consequently, a more frequent spinal cord invasion. However, initial infratentorial localization in our patient may explain in part the subsequent SLD. Other common causes of SLD should also be considered (proximity of the tumor to the CSF spaces, intraventricular breach during surgery…). In the literature, symptomatic SLD occurs in 2–5% of HGG [8], but may be present in 20–25% in autopsy series [3]. SLD is more frequent for infra-tentorial HGG, in a younger population [1, 3]. A retrospective analysis showed a median delay of 10 months before the emergence of SLD after glioma diagnosis, and 3 months between SLD and death [9]. It is suggested that molecular particularities could partly explain the prognosis discrepancies compared to the overall glioblastoma population (low frequency of EGFR alterations, high frequency of PDGFRA amplification) [1]. But to date, no specific molecular biomarker has been identified [5]. SLD is a difficult condition to treat, often occurring at advanced stages of the disease in highly pretreated patients. Radiotherapy seems to be a commonly discussed therapeutic option and systemic treatments appear less effective, limiting extrapolation of the benefits reported in intracranial gliomas [10]. However, combination of BEV with conventional treatment appears to be a therapeutic option [11, 12]. In our case, we report notable and prolonged functional response with respect to survival 5 years after diagnosis. It is difficult to determine which pharmacological effect of BEV explains its efficacy against leptomeningeal dissemination. BEV anti-edema effect is undisputed through normalization of vascular permeability. The extent of direct anti-glioma activity remains uncertain. The significant advantage in patients treated for SLD could be explained in part by neuroanatomy. The tumor is responsible for spinal cord compression in the spinal canal, making the anti-edematous effect of BEV more impressive [13]. The reduction in CSF pressure under BEV, along with the improvement of initially pathological CSF parameters, challenges the notion that BEV acts merely as an ‘expensive super-steroid’ in SLD. In patients with glioblastoma and SLD, BEV may induce regression of contrast-enhancing tumor areas as well as non-enhancing nodules on T2 sequences—an effect that extends beyond mere edema reduction [14]. Other studies have hypothesized that SLD might be facilitated by prior treatment with BEV in supratentorial gliomas, though no clear causal responsibility has been established [15]. In our patient, we could question the involvement of immunotherapy in response. Indeed, he received immunotherapy before BEV. Some cases of pseudo-progression have already been described in other cancer types in the literature. Several clinical cases of patients with hepatocellular carcinoma treated with the combination of atezolizumab and BEV initially exhibited pseudoprogression. However, follow-up scans conducted 2 months later revealed a significant therapeutic response, including the potential for complete response [16]. We hypothesized that the patient may have initially experienced pseudoprogression during immunotherapy, followed by a sustained response thereafter. Based on the description of this clinical case, it is not possible to attribute the observed radiological improvement, initial clinical benefit, or sustained response specifically to the efficacy of BEV, the effects of immunotherapy, or a potential combination of both. To our knowledge, there is no formal evidence demonstrating an interaction between these therapies. However, emerging hypotheses suggest that combining anti-angiogenic therapies with immunotherapy could potentially overcome resistance mechanisms in glioblastoma. Indeed, abnormal tumor vasculature is suspected of promoting immune evasion and contributing to the establishment of an immunosuppressive microenvironment [17, 18]. In conclusion, this young patient presents a molecularly distinct methylation class. Despite SLD and the typically poor prognosis of this disease, the patient experienced functional recovery and remains in sustained response. Based solely on this clinical case, it is not possible to determine whether certain characteristics of this patient are truly associated with adult-type diffuse high-grade glioma, IDH-wildtype, methylation subtype E. It would be relevant to establish a cohort of patients with comparable anatomopathological and molecular characteristics, as well as a similar response to immunotherapy and/or bevacizumab, in order to strengthen the hypothesis put forward in this clinical case. Identification of new subclass may help understanding differences in treatment responses and could lead to personalized therapy. For this reason, subgroups individualization is necessary in future HGG clinical trials.